XTX Topco Ltd Increases Stock Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

XTX Topco Ltd boosted its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 42.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,560 shares of the company’s stock after purchasing an additional 8,801 shares during the period. XTX Topco Ltd’s holdings in GoodRx were worth $231,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of GDRX. Rubric Capital Management LP purchased a new position in GoodRx in the fourth quarter worth $39,348,000. American Century Companies Inc. purchased a new position in GoodRx in the second quarter worth $18,183,000. Picton Mahoney Asset Management purchased a new position in GoodRx in the first quarter worth $3,467,000. Rip Road Capital Partners LP boosted its position in GoodRx by 25.8% in the fourth quarter. Rip Road Capital Partners LP now owns 1,763,277 shares of the company’s stock worth $11,814,000 after purchasing an additional 361,294 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in GoodRx in the first quarter worth $1,638,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.17% of the stock is owned by company insiders.

GoodRx Stock Performance

NASDAQ:GDRX opened at $6.85 on Friday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. GoodRx Holdings, Inc. has a 52-week low of $4.14 and a 52-week high of $9.26. The firm has a market cap of $2.60 billion, a price-to-earnings ratio of -684.32, a PEG ratio of 3.38 and a beta of 1.38. The business’s fifty day moving average is $7.81 and its 200 day moving average is $7.57.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The business had revenue of $200.60 million for the quarter, compared to analysts’ expectations of $200.47 million. During the same quarter in the previous year, the firm earned $0.02 earnings per share. GoodRx’s quarterly revenue was up 5.7% compared to the same quarter last year. Research analysts predict that GoodRx Holdings, Inc. will post 0.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on GDRX shares. Citigroup cut their price objective on GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price on the stock in a research note on Friday, August 9th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. UBS Group lowered their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. Finally, Morgan Stanley boosted their target price on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a research note on Monday, June 10th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.36.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.